SCHEMBL7122774

SCHEMBL7122774

COc1ccc(C2Oc3ccccc3NC2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.53
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
PGR P06401 1/20 0.47
MAPT P10636 3/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MAOB P27338 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
CA2 P00918 3/20 0.44
HSD17B10 Q99714 1/20 0.43
F10 P00742 1/20 0.43
BRD4 O60885 2/20 0.43
CREBBP Q92793 2/20 0.43
CYP19A1 P11511 1/20 0.43
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
MAOA P21397 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981242 0.83 ABCB1 (0.49) KMT2AMEN1PGRMAPTNPSR1
SCHEMBL5670399 0.83 CA2 (0.62) PARP1KMT2APGRCA2HSD17B10
SCHEMBL7271716 0.81 PARP1 (0.53) PARP1KMT2AMEN1PGRTNKS2
SCHEMBL10545135 0.79 CA2 (0.61) KMT2AMAPTNPC1RAB9AMAOB
SCHEMBL17634084 0.77 PARP1 (0.49) PARP1KMT2AMEN1PGRMAPT
SCHEMBL5745711 0.77 KMT2A (0.56) PARP1KMT2AMEN1HSD17B10BRD4
SCHEMBL17633666 0.76 CYP2C19 (0.43) KMT2AMEN1PGRNPC1RAB9A
SCHEMBL17634129 0.76 BRD4 (0.46) PGRNPC1RAB9AMAOBCA2
SCHEMBL14895951 0.72 MAPT (0.63) PGRMAPTNPSR1NPC1RAB9A
SCHEMBL4267781 0.72 KDM4E (0.52) PARP1KMT2AMEN1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors BERRYMAN KENT ALAN (US) 2003-10-02 US disclosed
US-6509335-B1 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of WARNER-LAMBERT COMPANY 2003-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors HABP2, SPINT2, SERPINB1 PARP1 1395/4885KMT2A 2288/4885MEN1 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.